Trial Profile
A Single Arm Phase II Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR Mutations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 15 Dec 2022 Status changed from active, no longer recruiting to completed.
- 30 Jun 2022 Planned primary completion date changed from 30 Jun 2022 to 30 Jun 2023.
- 22 Jun 2022 Status changed from recruiting to active, no longer recruiting.